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Abstract: The system redox imbalance is one of the pathways related to obesity-related cardiac
dysfunction. Lycopene is considered one of the best antioxidants. The aim of this study was to test if
the tomato-oleoresin would be able to recovery cardiac function by improving β-adrenergic response
due its antioxidant effect. A total of 40 animals were randomly divided into two experimental
groups to receive either the control diet (Control, n = 20) or a high sugar-fat diet (HSF, n = 20) for
20 weeks. Once cardiac dysfunction was detected by echocardiogram in the HSF group, animals
were re- divided to begin the treatment with Tomato-oleoresin or vehicle, performing four groups:
Control (n = 6); (Control + Ly, n = 6); HSF (n = 6) and (HSF + Ly, n = 6). Tomato oleoresin (10 mg
lycopene/kg body weight (BW) per day) was given orally every morning for a 10-week period. The
analysis included nutritional and plasma biochemical parameters, systolic blood pressure, oxidative
parameters in plasma, heart, and cardiac analyses in vivo and in vitro. A comparison among the
groups was performed by two-way analysis of variance (ANOVA). Results: The HSF diet was able
to induce obesity, insulin-resistance, cardiac dysfunction, and oxidative damage. However, the
tomato-oleoresin supplementation improved insulin-resistance, cardiac remodeling, and dysfunction
by improving the β-adrenergic response. It is possible to conclude that tomato-oleoresin is able to
reduce the oxidative damage by improving the system’s β-adrenergic response, thus recovering
cardiac function.
Keywords: high sugar-fat diet; obesity; β-adrenergic system; cardiac dysfunction; lycopene;
tomato-oleoresin
1. Introduction
Clinical studies show that the excessive body fat leads to many cardiac abnormalities, among them,
morphologic and functional changes [1,2]. Animal studies have demonstrated myocardial dysfunction
in obese rodents fed with hypercaloric diets [3–7]. Although it is evident that many cardiac changes
and/or impairments in performance occur due to adipose tissue accumulation [3,8], the responsible
mechanisms by which these changes are not clarified. The system redox unbalance, characterized
by a high production of reactive species and inefficient antioxidant activity, is one of the pathways
associated with the obesity-related cardiac dysfunction [9].
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The β-adrenergic system is one of the most important mechanisms responsible for myocardial
contraction and relaxation [10–12]. However, chronic expositions to reactive species are associated
with sustained adrenergic stimulation, resulting in arrhythmias and heart failure [13]. Considering the
redox system’s role in the pathogenesis of obesity and cardiac disorders, the use of antioxidants as
therapeutic strategies has been tested [14,15].
Lycopene is a carotenoid present in tomato and red fruits and considered a potent antioxidant [16–18].
The tomato, and tomato product consumption are one of the Mediterranean diet’s characteristics,
which is associated with health benefits [18]. However, there is a lack of studies regarding lycopene
dose ingestion in countries with a Mediterranean diet. Moreover, the few studies which bring
information about lycopene consumption have a big variability [19] among the results (for example:
in Italy the average intake is 7.4 mg per day while in Spain is 1.6mg per day [18]). The effect of
lycopene on cardiovascular disease has been evaluated in clinical [20,21] and experimental studies [22].
Although obesity and oxidative stress are able to lead to cardiac dysfunction, no studies have evaluated
the cardiac modulation by lycopene due the antioxidant effect. So, this study aimed to test if the
tomato-oleoresin would be able to recovery the cardiac function by improving β-adrenergic response
due its antioxidant effect.
2. Materials and Methods
2.1. Animals and Experimental Protocol
In the present study, male Wistar rats (±187 g) were initially divided into two experimental
groups to receive control diet (Control, n = 20) or high sugar-fat diet (HSF, n = 20) for 20 weeks. The
diets and water were provided ad libitum. The diet composition has been described in our previous
studies [15,23]. All the animals were housed in an environmental controlled room (22 ◦C ± 3 ◦C,
12 h light-dark cycle and relative humidity of 60 ± 5%). All of the experiments were performed in
accordance with the National Institute of Health’s Guide for the Care and Use of Laboratory Animals
and the procedures were approved by the Animal Ethics Committee of Botucatu Medical School
(1196/2016).
At week 20 of this study, the cardiac dysfunction was detected by echocardiogram in the HSF
group. Thus, the animals were casually divided to begin the treatment with tomato-oleoresin or vehicle,
performing four groups: Control (n = 6); Control supplemented with lycopene- tomato oleoresin
(Control + Ly, n = 6); HSF (n = 6) and HSF supplemented with lycopene- tomato oleoresin (HSF + Ly,
n = 6). Tomato oleoresin was mixed with corn oil correspondent to 10 mg lycopene/kg of body weight
(BW) per day and given orally every day, in the morning, for a 10-week period [24,25]. To avoid
differences in the energy provided, all the groups received the same corn oil amount (about 2 ml/kg
BW per day). The supplementation time and dose were chosen based in previous studies from our
research group and others from the literature [24–26].
2.2. Tomato-Oleoresin Preparation
The tomato-oleoresin (Lyc-O-Mato 6% dewaxed; LycoRed Natural Products Industries, Beersheba,
Israel) was mixed with corn oil and kept in the dark, at 4 ◦C, until the moment to be used [27]. The
tomato oleoresin-corn oil mixture stayed for 20 min in a water-bath at 54 ◦C before the animals receive.
The total amount of lycopene in each solution was 5mg/ml. Lycopene stability was confirmed by
diode-array spectra at 450 nm, as previously described [28].
2.3. Nutritional Evaluation
Nutritional evaluation included: feed consumption (FC)-daily consumed amount in grams of
chow feed; final body weight (BW); caloric intake (CI), calculating according to the following formula
for the control group: caloric intake (kcal/day) = feed consumption (g) × dietary energy (3.59 kcal/g).
For the HSF group, the caloric intake was calculated as following: water volume consumed (mL) ×
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0.25 (equivalent to 25% fructose) × 4 (calories per gram of carbohydrate) + caloric intake providing by
the chow (feed consumption (g) × dietary energy (4.35 kcal/g).
Feed efficiency (FE) is defined as the ability to convert the caloric intake to body weight. It was
calculated according to the formula: FE (%) = BW gain (g)/total caloric intake (kcal) × 100 [15,23]. The
adiposity index, considered an obesity marker, was calculated as follow: adiposity index = (total body
fat (BF)/final body weight) × 100. BF was evaluated considering the sum of the individual fat pad
weights: BF = epididymal fat + retroperitoneal fat + visceral fat.
2.4. Metabolic and Hormonal Analysis
The plasma used for the biochemical analysis was collected after 12 h of fasting. The glucose levels
were evaluated by a glucometer (Accu-Chek Performa; Roche Diagnostics, Indianapolis, IN, USA). The
insulin levels were analyzed by ELISA assay with commercial kits (Millipore) [23]. The HOMA-IR
(homeostatic model of insulin resistance), considered an insulin resistance index, was calculated by the
following formula: HOMA-IR = [fasting glucose (mmol/L) × fasting insulin (µU/mL)]/22.5 [15].
2.5. Systolic Blood Pressure (SBP)
SBP was evaluated by a non-invasive tail-cuff method with a NarcoBioSystems®
Electro-Sphygmomanometer (International Biomedical, Austin, TX, USA) with the conscious rats. For
this, the animals were heat during 4–5min in a wooden box (50 × 40 cm), with two incandescent lamps
and temperature between 38–40 ◦C, to induce arterial vasodilation in the tail. Then, the rats were
transferred to an iron cylindrical support specially made to allow the total exposure of the animal’s
tail [29]. After this procedure, a cuff with a pneumatic pulse sensor was attached to the tail and inflated
to 200 mmHg pressure and successively deflated. Blood pressure values were documented on a Gould
RS 3200 polygraph (Gould Instrumental Valley View, Cleveland, OH, USA). The final SBP of each
animal considered the average of three pressure readings.
2.6. Lycopene Bioavailability Evaluation
The presence of lycopene was determined in plasma and cardiac tissue homogenate. To extract
the carotenoids, samples were incubated with internal standard (equinenone), chloroform/methanol
CHCl3/CH3OH (3 mL, 2:1, v/v) and 500 mL of saline 8.5 g/L. Then the samples were centrifuged
at 2000× g for 10 min and the supernatant was collected and hexane was added. The chloroform
and hexane layers were evaporated under nitrogen and the residue was resuspended in 150 mL
of ethanol and sonicated for 30 s. 50 µL of this aliquot was injected into the HPLC. The HPLC
system was a Waters Alliance 2695 (Waters, Wilmington, MA, USA) and consisted of pump and
chromatography bound to a 2996 programmable photodiode array detector, a C30 carotenoid column
(5 µm, 150 × 4.6 mm, YMC-Yamamura Chemical Research, Wilmington, NC, USA), and Empower
software (Empower 3, chromatographic data software Milford, MA, USA). The HPLC system
programmable photodiode array detector was set at 450 nm for carotenoids. The mobile phase
consisted of ethanol/methanol/methyl-tert-butyl ether/water (83:15:2, v/v/v, 15 g/L with ammonium
acetate in water, solvent A) and methanol/methyl-tert-butyl ether/water (8:90:2, v/v/v, 10 g/L with
ammonium acetate in water, solvent B). The gradient procedure, at a flow rate of 1 mL/min (16 ◦C),
was as follows: (1) 100% solvent A was used for 2 min followed by a 6 min linear gradient to 70%
solvent A; (2) a 3 min hold followed by a 10 min linear gradient to 45% solvent A; (3) a 2 min hold,
then a 10 min linear gradient to 5% solvent A; (4) a 4 min hold, then a 2 min linear gradient back to
100% solvent A. For the quantification of the chromatograms, a comparison was made between the
area ratio of the substance and area of the internal standard obtained in the analysis [30].
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2.7. Cardiac Malondialdehyde (MDA) Levels
MDA is the main lipid peroxidation marker. It is considered an oxidative stress index [31] and
associated with cardiovascular diseases [32]. Thus, MDA levels were used to evaluate the cardiac lipid
oxidation as follow:
Cardiac tissue (±150 mg) was homogenized (ULTRA-TURRAX®T25 basic IKA® Werke
Staufen/Germany) with 1.0 mL of cold phosphate buffered saline (PBS) pH 7.4, and centrifuged
at 800 g at 4 ◦C for 10 min. Then, 100 µL from the supernatant was mixed with 700 µL of 1%
orthophosphoric acid and 200 µL of thiobarbituric acid (42 mM). After this, the samples were kept at
100 ◦C for 60 min in a water bath, and immediately cooled on ice. In a 2 mL tube, 200 µL was mixed
with 200 µL sodium hydroxide/methanol (1:12 v/v). After vortex, the samples were centrifuged for
3 min at 13,000 g. 200 µL from the supernatant was transferred to a glass vial and 50µL was injected into
the column. The HPLC used was a Shimadzu LC-10AD system (Kyoto, Japan) with a C18 Luna column
(5 µm, 150 × 4.60 mm, Phenomenex Inc., Torrance, CA, USA), and a Shimadzu RF-535 fluorescence
detector (excitation 525 nm, emission 551 nm), and 0.5mL/min phosphate buffer flow (KH2PO4 1mM,
pH 6.8) [25]. The MDA levels considered the peak area determination in the chromatograms relative to
the standard curve of known concentrations.
2.8. Circulating Advanced Oxidation Protein Products
Advanced oxidation protein products (AOPPs) are oxidized plasma proteins resulting from the
exposure to oxidation products and are transported by albumin in the circulation [33]. The literature
reports that high AOPP circulating levels contribute to cardiac diseases [34].
AOPP determination was based on spectrophotometric detection according to Kalousova et al. [35].
Plasma samples (200µL) were diluted 1:5 with PBS. It was also used 200µL of chloramin T (0–100µmol/L)
for calibration curve and the blank was only PBS (200 µL). All the samples were put on a microtiter
plate and mixed with 10 µL of KI 1.16 M and 20 µL of acetic acid. The absorbance was measured
immediately at 340 nm (spectrophotometer Multiskan Ascent, Labsystems, Vantaa, Finland). The final
AOPP concentration is expressed in chloramine units (µmol/L).
2.9. Circulating Carboxymethyl Lysine
Advanced glycation end products (AGEs) are a group of several molecules generated by both
non-enzymatic glycation and protein, lipids and nucleic acids oxidation, able to modify tissue function
and mechanical properties [36]. In vivo, CML is the main AGE associated with cardiac pathologies [37].
The plasmatic carboxymethyl lysine (CML) levels were evaluated using an ELISA commercial kit
(OxiSelect™ CML, Cell Biolabs Inc., San Diego, CA, USA) following the manufacturer’s instructions.
2.10. Echocardiographic Study
The analyze was performed in the live animals by transthoracic echocardiography, with a Vivid S6
system equipped with multifrequency ultrasonic transducer 5.0 to 11.5 MHz (General Electric Medical
Systems, Tirat Carmel, Israel). The animals were lightly anesthetized by intraperitoneal injection
with a mixture of ketamine (50 mg/kg) and xylazine (1 mg/kg), put in left decubitus position and
only one examiner made all the exams. The heart image structural measurements were obtained in
one-dimensional mode (M-mode) guided by the images in two-dimensional mode with the transducer
in the parasternal position, minor axis. Left ventricular (LV) evaluation was performed with the cursor
M-mode just below the mitral valve plane at the level of the papillary muscles. The aorta and left
atrium images were obtained by positioning the M-mode course to plan the aortic valve level [23].
The following cardiac structures were evaluated: diastolic diameter (LVDD); systolic (LVSD) LV;
left ventricle diastolic thickness posterior wall (LVPWD); aorta diameter (AD); left atrium (LA). The
LV diastolic function was assessed by the transmitral flow early peak velocity (E). The LV systolic
function was evaluated by ejection fraction and posterior wall shortening velocity (PWSV). The
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joint assessment of diastolic and systolic LV function was performed using the Tei index (sum of
isovolumetric contraction and IRT time, divided by the left ventricular ejection time). The study was
complemented by tissue Doppler evaluation, considering early diastolic (E’), and late (A’) of the mitral
annulus (arithmetic average travel speeds of lateral and septal walls), and the ratio by the waves E and
E’ (E/E’).
2.11. Myocardial Function by Isolated Papillary Muscle Study
Besides echocardiographic analysis, myocardial function was also assessed by LV isolated
papillary muscles. This procedure has been used by several authors [6,7,29]]. Conventional
mechanical parameters at Lmax were calculated from isometric contraction: maximum developed
tension normalized per cross-sectional area (DT [g/mm2]), resting tension normalized per cross-sectional
area (RT [g/mm2]), positive (+dT/dt [g/mm2/s]) and negative (−dT/dt [g/mm2/s]) tension derivative
normalized per cross-sectional area of papillary muscle (CSA).
2.12. β-Adrenergic System Study
β-adrenergic receptors (βAR) are important to regulate cardiac function in both normal and
pathologic conditions [11]. The receptors activity was assessed by the dose-response relationship
between the isoproterenol and conventional mechanical parameters of papillary muscle at Lmax. After
baseline values determination, the isoproterenol was added to the vat in the presence of 1.0 mM [Ca2+]
to increase progressively the concentrations for 10−8, 10−7 and 10−6 mol/L.
The stabilization of contractile response occurs nearly 3–5min after adding each isoproterenol dose.
Data were sampled and expressed as the stimulation mean percent (%) [29]. At the end of the study,
length (mm), weight (mg), and CSA (mm2) [38] were measured for papillary muscle characterization.
The CSA was calculated from papillary muscle length and weight, assuming uniformity and a specific
gravity of 1.0. The muscle length at Lmax was measured with a cathetometer (Gartner Scientific
Corporation, Chicago, IL, USA), and the muscle between the two clips was blotted dry and weighed.
2.13. Statistical Analysis
The results are expressed in mean ± standard deviation (SD). Two-way analysis of variance
(ANOVA) for independent samples was used to determine the differences among the groups.
In order to evaluate the positive and negative inotropic effects on myocardial function, it was
used a repeated-measures two-way ANOVA. Once detected significant differences (p < 0.05), the Tukey
post hoc test for multiple comparisons were carried out. All the statistical analyses were performed
using SigmaStat for Windows (Version 3.5, San Jose, CA, USA).
3. Results
The lycopene bioavailability is presented in the Table 1. It is possible to verify the presence of
lycopene in both groups, which were supplemented (Control + Ly and HSF + Ly).
The HSF group presented increased caloric intake (kcal/d), final body weight (g), adiposity index,
glucose levels, HOMA-IR and systolic blood pressure values compared to the control group. The
HSF + Ly showed the same changes observed in HSF group when compared to control + Ly, except
for HOMA-IR. Tomato-oleoresin suppressed the insulin resistance in HSF + Ly compared to HSF
(Figure 1). No effect was observed of tomato-oleoresin on the other parameters.
Table 1. Lycopene Bioavailability.
Lycopene Concentration Groups
Control Control + Ly HSF HSF + Ly
Plasma (µg/mL) ND 3.61 ± 0.68 ND 3.59 ± 2.31
Heart (µg/g of tissue) ND 4.83 ± 2.37 ND 2.41 ± 0.36
Data are expressed in mean ± standard deviation (n = 4 animals/group). ND: Not detectable.
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Figure 1. Nutritional and cardio- metabolic parameters. A—caloric intake (kcal/day); B—adiposity 
index (%); C—final body weight (g); D—glucose (mg/dL); E—HOMA-IR; F—systolic blood pressure 
(mmHg). Data are expressed in mean ± standard deviation (n = 6 animals/group). Comparison by 
Two-way ANOVA with Tukey post-hoc (p < 0.05): *HSF vs Control; #HSF vs HSF + Ly; $HSF + Ly vs 
Control + Ly. 
The HSF group presented cardiac remodeling (increased LVDS, LVPWD and reduced LVDD), 
and deterioration of both systolic (decreased ejection fraction, Tei-a and Tei-b) and diastolic 
(increased E/E′ and decreased Tei-a and Tei-b) functions compared to control group. Regarding the 
tomato-oleoresin supplementation effect, HSF + Ly group showed improvement in some remodeling, 
systolic and diastolic parameters compared to HSF (Table 2). 
Table 2. Echocardiographic study. 
Variables 
Groups  Effect 
Control Control + Ly HSF HSF + Ly Diet Ly Interaction 
LVDD (mm) 7.15 ± 0.11 7.02 ± 0.11 6.70 ± 0.12 * 6.92 ± 0.11 0.019 0.665 0.123 
LVDS (mm) 2.83 ± 0.10 2.74 ± 0.10 3.17 ± 0.11 * 2.91 ± 0.10 0.016 0.098 0.417 
LVPWD (mm) 1.63 ± 0.04 1.53 ± 0.04 1.73 ± 0.04 * 1.62 ± 0.04 # 0.031 0.014 0.932 
AD (mm) 3.91 ± 0.06 3.86 ± 0.06 3.89 ± 0.07 3.88 ± 0.06 0.999 0.682 0.740 
LA (mm) 4.86 ± 0.11 4.85 ± 0.11 5.02 ± 0.11 4.88 ± 0.11 0.388 0.483 0.536 
HR (bpm) 254 ± 14 265 ± 14 262 ± 15 262 ± 14 0.871 0.716 0.713 
E (cm/s) 73.6 ± 2.1 73.2 ± 2.18 76.1 ± 2.1 75.1 ± 2.3 0.351 0.742 0.895 
PWSV (cm/s) 58.6 ± 1.3 61.1 ± 1.3 56.1 ± 1.3 59.8 ± 1.4 0.181 0.028 0.622 
Dec. time (ms) 47.2 ± 1.3 42.1 ± 1.3 50.6 ± 1.3 42.7 ± 1.4 0.128 <0.001 0.322 
Tei-a (ms) 116.1 ± 2.5 116.8 ± 2.5 99.1 ± 2.5 * 111.7 ± 2.6 # <0.001 0.012 0.024 
Tei-b (ms) 86.6 ± 2.9 92.6 ± 2.9 77.7 ± 2.9 * 85.5 ± 3.1 # 0.012 0.028 0.761 
EF (%) 0.93 ± 0.008 0.93 ± 0.008 0.88 ± 0.008 * 0.93 ± 0.008 # <0.001 0.006 0.008 
E/E' 13.3 ± 0.4 12.7 ± 0.4 15.3 ± 0.4 * 13.9 ± 0.50 # 0.002 0.049 0.439 
Data are expressed in mean ± standard deviation (n = 6 animals/group). Comparison by Two-way 
ANOVA with Tukey post-hoc (p < 0.05): *HSF vs Control; #HSF vs HSF+Ly. LVDD, left ventricular 
Figure 1. Nutritional and cardio- metabolic parameters. A—caloric intake (kcal/day); B—adiposity
index (%); C—final body weight (g); D—glucose (mg/dL); E—HOMA-IR; F—systolic blood pressure
(mmHg). Data are expressed in mean ± standard deviation (n = 6 animals/group). Comparison by
Two-way ANOVA with Tukey post-hoc (p < 0.05): * HSF vs Control; # HSF vs HSF + Ly; $ HSF + Ly vs
Control Ly.
The sented cardiac remodeling (increased LVDS, LVPWD an reduced LVDD), and
deterioration of both sys olic (decreas d ejection fraction, Tei-a and Tei-b) and diastolic (increased E/E′
and decreased Tei-a and Tei-b) functions compared to control gr up. Regarding the tomato-oleoresin
supplementation effect, HSF + Ly group showed improvement in some remodeling, systolic and
diastolic parameters compared to HSF (Table 2).
Table 2. Echocardiographic study.
Variables
Groups Effect
Control Control + Ly HSF HSF + Ly Diet Ly Interaction
LVD (m ) 7.15 1 7.02 ± 0.11 6.70 ± 0.12 * 6.92 ± 0.11 0.019 0.665 0.123
LVDS (mm) 2.83 ± 0.10 2.74 ± 0.10 3.17 ± 0.11 * 2.91 ± 0.10 0.016 0.098 0.417
LVPWD (mm) 1.63 ± 0.04 1.53 ± 0.04 1.73 ± 0.04 * 1.62 ± 0.04 # 0.031 0.014 0.932
AD (mm) 3.91 ± 0.06 3.86 ± 0.06 3.89 ± 0.07 3.88 ± 0.06 0.999 0.682 0.740
LA (mm) 4.86 ± 0.11 4.85 ± 0.11 5.02 ± 0.11 4.88 ± 0.11 0.388 0.483 0.536
HR (bpm) 254 14 265 ± 14 262 ± 15 262 ± 14 0.871 0.716 0.713
E (cm/s) 7 . . 73.2 ± 2.18 76.1 ± 2.1 75.1 ± 2.3 0.351 0.742 0.895
PWSV (cm/s) 58.6 ± 1.3 61.1 ± 1.3 56.1 ± 1.3 59.8 ± 1.4 0.181 0.028 0.622
Dec. time (ms) 47.2 ± 1.3 42.1 ± 1.3 50.6 ± 1.3 42.7 ± 1.4 0.128 <0.001 0.322
Tei-a (ms) 116.1 ± 2.5 116.8 ± 2.5 99.1 ± 2.5 * 111.7 ± 2.6 # <0.001 0.012 0.024
Tei-b (ms) 86.6 ± 2.9 92.6 ± 2.9 77.7 ± 2.9 * 85.5 ± 3.1 # 0.012 0.028 0.761
EF (%) 0.93 ± 0.008 0.93 ± 0.008 0.88 ± 0.008 * 0.93 ± 0.008 # < .001 0.006 0.008
/E’ 1 .3 ± 0.4 12.7 ± .4 15.3 ± 0.4 * 13.9 ± 0.50 # 0.002 0. 49 0.439
Data are expressed in mean ± standard deviation (n = 6 animals/group). Comparison by Two-way ANOVA with
Tukey post-hoc (p < 0.05): * HSF vs Control; # HSF vs HSF+Ly. LVDD, left ventricular diastolic diameter; LVSD, left
ventricular systolic diameter; LVPWD, diastolic thickness posterior wall of the left ventricle; AD, aorta diameter; LA,
left atrium diameter during ventricular systole; HR, heart rate; E, E-wave peak transmitral early diastolic inflow
velocity; PWSV, posterior wall shortening velocity; Dec. time, deceleration time; Transmitral flow, Tei-a and Tei-b;
EF, ejection fraction; E/E’.
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The myocardial papillary muscle study at baseline condition with 2.5 mM Ca2+ is presented in the
Table 3. HSF group showed functional impairment in the maximum developed tension (DT) compared
to control group. Tomato-oleoresin supplementation was effective to recovery the DT capacity in HSF
+ Ly group compared to HSF (Table 3).
Table 3. Isolated papillary muscle at baseline condition (2.5 mM Ca2+).
Variables
Groups Effect
Control Control +Ly HSF HSF + Ly Diet Ly Interaction
DT(g/mm2) 5.96 ± 1.25 6.29 ± 1.65 4.41 ± 1.11 * 6.05 ± 1.19 # 0.066 0.046 0.173
RT(g/mm2) 0.65 ± 0.11 0.61 ± 0.11 0.63 ± 0.08 0.57 ± 0.11 0.512 0.202 0.844
+dT/dt(g/mm2/s) 61.9 ± 10.1 63.5 ± 18.4 60.8 ± 11.7 65.5 ± 19.7 0.934 0.573 0.773
−dT/dt(g/mm2/s) 16.8 ± 2.4 17.5 ± 2.9 15.5 ± 3.3 16.1 ± 2.9 0.193 0.569 0.933
CSA(mm2) 1.11 ± 0.12 1.10 ± 0.23 1.25 ± 0.27 1.17 ± 0.3 0.181 0.801 0.912
Data are expressed in mean ± standard deviation (n = 6 animals/group). Comparison by Two-way ANOVA with
Tukey post-hoc (p < 0.05): * HSF vs Control; # HSF vs HSF+Ly. DT, Maximum developed tension normalized per
cross-sectional area of the papillary muscle; RT, Resting tension normalized per cross-sectional area of the papillary
muscle; peak of the positive, +dT/dt and negative, −dT/dt tension derivatives normalized per cross-sectional area of
the papillary muscle; CSA, cross-sectional area.
Figure 2 shows the β-adrenergic stimulation on the papillary muscle function. The isoproterenol
stimulation demonstrated that the HSF group presented functional impairment in DT (10−6 M) and
−dT/dt (10−7 and 10−6 M) compared to control group. Tomato-oleoresin supplementation was effective
to recover the −dT/dt (10−7 and 10−6 M) capacity in HSF + Ly group compared to HSF.
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Figure 3 shows the oxidative stress parameters in plasma and cardiac tissue. All the parameters 
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Figure 2. β-adrenergic stimulation in papillary muscles. Data are expressed in mean ± standard
deviation (n = 6 animals/group). Baseline calcium concentration (1.0 mM) is presented as 100%. A,
Maximum de ped tension normalized per r ss-sectional area [DT, g/mm2]. B, positive [+dT/dt,
g/mm2/s] and C, negative [−dT/dt, g/mm2/s] tension derivative normalized per cross-sectional area of
the papillary muscle. Two-way ANOVA repeated-measures with Tukey post-hoc was used to compare
the groups (p < 0.05); * HSF vs Control; # HSF vs HSF + Ly.
Figure 3 shows the oxidative stress parameters in plasma and cardi c tissue. All the parameters
increased in HSF group compared to control group. By contrast, it is possible to note that CML, AOPP
and cardiac MDA plasma levels reduced in HSF + Ly group in respect to HSF to demonstrate a positive
effect of tomato-oleoresin.
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4. Discussion
This study aimed to test if the tomato-oleoresin would be able to recovery the cardiac function
by improving β-adrenergic response due its antioxidant effect. The results show that the HSF groups
presented with obesity, characterized by the higher values of body weight and adiposity index, and
metabolic syndrome, with insulin resistance, dyslipidemia, and hypertension, all diseases usually
associated with obesity [39]. These findings confirm that the diet model used in this study was
efficient to lead obesity and related disorders, corroborating the literature [6,7,15,23]. Regarding the
lycopene effect on obesity and related disorders, it was observed a positive action only on insulin
resistance in the HSF + Ly group, represented by the reduction in HOMA-IR. The literature attributes
the tomato-oleoresin benefic effects on diabetes to the lycopene antioxidant potential [40]. Another
explanation for this amelioration is the anti-inflammatory effect of tomato-oleoresin. Since insulin
resistance and type 2 diabetes are conditions closely related with inflammation and studies already
showed that tomato-oleoresin ameliorates the inflammation, this property may explain the beneficial
effect on glucose metabolism [41]. The antioxidant and anti-inflammatory effect of lycopene can
also be explained by considering its well-established ability, through electrophilic metabolites, to
activate Nrf2 pathway thus inducing phase II detoxifying/antioxidant enzymes and inhibiting NF-κB
activation [42–44].
Obesity is also associated with cardiac abnormalities, among them morphological, hemodynamic
and functional alterations [1,8,23]. Considering the lycopene absence effect on obesity and
hypertension in the HSF + Ly group, should both HSF groups present cardiac damage. However, the
echocardiographic analysis showed cardiac remodeling and impairment in ventricular systolic and
diastolic function only in HSF group after 30 weeks. In opposition, the HSF group supplemented with
tomato-oleoresin showed a cardiac remodeling and function recovery.
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Several mechanisms could explain the obesity-induced cardiac dysfunction, among them is the
β-adrenergic system responsiveness. The myocardial β-adrenergic mechanism is the main responsible
by regulating the cardiac performance, especially by intracellular Ca2+ handling [6,7]. Although
functional studies using isolated papillary muscle have showed that obesity is able to lead to impairment
in cardiac contractile [3,5,7], a small number of studies have evaluated the β-adrenergic response in
high sugar-fat diet obesity-induced experimental models [29,45–49]. Our results demonstrated that
the isoproterenol stimulation leaded to negative responses in both systolic (DT) and diastolic (−dT/dt)
response in the HSF group while the HSF + Ly group showed an improvement in the β-adrenergic
response. However, it is still unclear how the high sugar-fat diet obesity-induced leads to a reduction
in the β-adrenergic response.
One hypothesis for the β-adrenergic response impairment is the chronic exposition to reactive
oxygen species (ROS) promoted by obesity [9,50]. The literature reports that the direct contact with
ROS exerts the same action of isoproterenol on β-adrenergic response, increasing the calcium transient
amplitude, therefore, exerting a modulator role in the myocardial contractility [13]. However, this
continues exposition to ROS may result in deleterious effects and contribute the development of cardiac
arrhythmias and failure [9]. Considering the lycopene antioxidant effect, the amelioration in the
β-adrenergic responsiveness of the HSF + Ly group can be attributed to this carotenoid property [14].
Another hypothesis is that the redox system imbalance in obesity conditions may lead to
damage to lipids and proteins, generating such biomarkers as MDA, CML and AOPP, which were
evaluated in this study [33,51–53]. These oxidative products can damage directly the cardiac tissue
by altering its geometry and functionality, or indirectly by the carbonylation of proteins involved
in the myocardial contractility regulatory response, as the β-adrenergic pathway [13,54,55]. While
the HSF group presented higher levels of MDA, CML and AOPP and cardiac function deterioration,
the tomato-oleoresin antioxidant effect is confirmed by reduced levels of these markers and cardiac
function recovery in the HSF + Ly group.
5. Conclusions
In summary, this study found that the HSF diet induced obesity-related cardiac dysfunction and
the tomato-oleoresin was able to attenuate this condition. Therefore, it is possible to conclude that
tomato-oleoresin is able to reduce oxidative damage, thereby improving the system’s β-adrenergic
response and recovering cardiac function.
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